Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Akebia Therapeutics Inc | AKBA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.37 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.37 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.65 - 2.48 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.37 | USD |
Akebia Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 286.84M | 209.37M | - | 194.62M | -51.93M | -0.25 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Akebia Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKBA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.40 | 1.435 | 1.31 | 1.37 | 2,506,806 | -0.03 | -2.14% |
| 1 Month | 2.06 | 2.48 | 1.31 | 1.69 | 7,851,489 | -0.69 | -33.50% |
| 3 Months | 1.65 | 2.48 | 1.31 | 1.71 | 4,934,487 | -0.28 | -16.97% |
| 6 Months | 0.83 | 2.48 | 0.7801 | 1.58 | 3,160,600 | 0.54 | 65.06% |
| 1 Year | 0.65 | 2.48 | 0.65 | 1.44 | 2,480,224 | 0.72 | 110.77% |
| 3 Years | 3.05 | 4.33 | 0.241 | 1.32 | 3,777,079 | -1.68 | -55.08% |
| 5 Years | 6.73 | 13.78 | 0.241 | 2.42 | 3,479,211 | -5.36 | -79.64% |
Akebia Therapeutics Description
| Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. |
